AbbVie (ABBV) stock surged 3.2% on positive news from EMA about label expansion for Skyrizi

From Nasdaq: 2024-06-03 02:33:00

AbbVie (ABBV) saw a 3.2% rally in shares to close at $161.24 due to increased trading volume. This jump followed positive news from the EMA on label expansion for their drug Skyrizi. The company is expected to post earnings of $3.05 per share, a 4.8% increase year-over-year, with revenue of $12.46 billion.

In comparison, Johnson & Johnson (JNJ) closed 1% higher at $146.67. Their upcoming EPS estimate is $2.73, showing a -2.5% change from last year. JNJ currently holds a Zacks Rank of #3 (Hold). Zacks experts have singled out an under-the-radar chemical company with potential explosive upside in the market. Investors are eyeing this stock that could rival recent successful picks like Boston Beer Company and NVIDIA.



Read more at Nasdaq: AbbVie (ABBV) Soars 3.2%: Is Further Upside Left in the Stock?